Comparison of the ocular surface microbiota in meibomian gland dysfunction patients and healthy subjects

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210221002

Enrollment

Registered

2021-02-21

Start date

2021-06-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meibomian gland dysfunction patients Meimobian gland dysfunction (MGD) blepharitis ocular microbiota bacteria 16S rDNA meibum

Interventions

Patients with Meibomian gland dysfunction at Outpatient clinic, department of ophthalmology, King Chulalongkorn Memorial Hospital,Healthy controls at Outpatient clinic, department of ophthalmology, Ki

Basic Science,Basic Science

MGD patients,Healthy controls

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: MGD patients 1) Adult patients aged 18-80 years with a chief complaint of one of the following symptoms: dryness, foreign body sensation, burning, or tearing. 2) A diagnosis of MGD with two or more of the following signs : redness or thickening of the lid margin, telangiectasia, reduced or no secretions, poor quality secretions, and gland obstruction. 3) If both eyes are involved, the investigator (U.R.) will randomly select only one eye. Healthy controls 1) No chief complaint of any dry eye symptoms or tear break up time (TBUT) is equal to or longer than 5 seconds without obvious dry eye symptoms. 2) MG associated assessments do not meet the criteria for diagnosis of MGD. 3) Corneal staining is negative 4) If both eyes are involved, the investigator (U.R.) will randomly select only one eye.

Exclusion criteria

Exclusion criteria: Both MGD patients and Healthy controls 1) Use topical or systemic antibiotics within the past month 2) Use other topical eye drops within 3 months (other than artificial tears) 3) Use contact lenses within the past month 4) Active allergies, infections, or inflammatory diseases of the ocular surface unrelated to dry eye or MGD 5) A history of ocular trauma or surgery within one year 6) Has systemic diseases affecting the ocular surface 7) Healthcare workers

Design outcomes

Primary

Measure	Time frame
bacterial identification in MGD patients and healthy controls cross section 16s rRNA sequencing	—

Secondary

Measure	Time frame
Tear cytokines level in MGD patients and healthy controls Cross section Luminex using a cytokine kit	—

Countries

Thailand

Contacts

Public ContactUbonwan Rasaruck

Department of ophthalmology, King Chulalongkorn Memorial Hospital

dr.ubonwanr@gmail.com022564142

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026